Geron Corporation
Geron Corporation (Nasdaq: GERN) is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for blood cancers. Its lead product, RYTELO (imetelstat), is a telomerase inhibitor approved in the United States and European Union for certain adults with transfusion-dependent anemia… From the company’s description.
Over the twelve months to Sep 30, 2026, Geron Corporation reported revenue of $217.52M, up 18.6% from a year earlier, and a net loss of $47.83M. Its operating margin was −14.7%, and operations used $90.53M in cash. In fiscal 2025, it reported revenue of $183.88M, up 138.8% from fiscal 2024, and a net loss of $83.50M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Geron Corporation does
In the company’s own words
Geron Corporation (Nasdaq: GERN) is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for blood cancers. Its lead product, RYTELO (imetelstat), is a telomerase inhibitor approved in the United States and European Union for certain adults with transfusion-dependent anemia due to lower-risk myelodysplastic syndromes (MDS). Geron markets RYTELO in the United States and is pursuing access and commercialization through third parties in Europe and other international markets. The company is also evaluating imetelstat in clinical trials for relapsed or refractory myelofibrosis, frontline myelofibrosis, higher-risk MDS and acute myeloid leukemia, and conducts research into next-generation telomerase inhibitors. Geron operates as a single business focused on RYTELO and imetelstat development, with no reportable segments described. RYTELO was developed internally, and Geron holds global commercial rights. The company launched the product in the United States in June 2024 and received European Commission approval in March 2025. Its website is www.geron.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- FOSTER CITY, CA
- Fiscal year end
- December
- CIK
- 886744
- SIC
- 2834
Financial performance, year by year
Fiscal 2011–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Geron Corporation — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Geron Corporation’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Geron Corporation and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Geron Corporation's earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Geron Corporation's last four quarterly filings that the numbers alone won't show?”